You are here: Industry Insights > MES

News List

The Role of Exosomes in Drug Delivery: A Natural Alternative to Synthetic Nanocarriers? Nurah Ekhlaque
April 09, 2025
Explore how exosome-based nanocarriers are shaping precision medicine by supporting targeted drug delivery in cancer and neurodegenerative diseases, with potential for reduced side effects.
Advances in Research on New Therapeutic Drugs for Myelodysplastic Syndromes (Part Two) Xiaomichong
July 09, 2024
In recent years, with the deepening of research into the pathogenesis of myelodysplastic syndromes (MDS), many novel drugs have emerged.
Advances in Research on New Therapeutic Drugs for Myelodysplastic Syndromes (Part one) Xiaomichong
July 09, 2024
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic malignancies characterized by defective normal hematopoiesis leading to a reduction in blood cells, with a risk of transformation into acute myeloid leukemia.
From CDMO Pharmaceutical Crisaborole First Generic Drug, Look at the Domestic PDE-4 Inhibitor R&D Development Layout Xiaobin
May 06, 2024
The NMPA official website showed that Zhejiang CDMO Pharmaceutical had submitted an application for the marketing application of crisaborole ointment as a generic drug and it was accepted by the Center for Drug Evaluation.
Domestic New Drug R&D Strength is Gradually Ascending, and Overseas Product Authorization is in Full Swing WND/PharmaSources
December 14, 2023
On November 13th, LEGN.US reached an 1 billion US dollar cooperation agreement with Novartis Pharmaceuticals.
Next Stop for PD-1? MNC for Subcutaneous Preparation Takes the Lead in Competition, Leading to A More Fierce Domestic Conpetition, but Differentiation is not easy Spur 203/PharmaSources
December 14, 2023
The competition for the subcutaneous formulation of PD-1/PD-L1 inhibitors has been spreading globally for a long time, with Roche and Bristol Myers Squibb currently leading the pack.
Initial CRISPR Gene Editing Therapy has been Approved. What is the Domestic Progress? Yefenghong/PharmaSources
December 14, 2023
Vertex Pharmaceuticals and CRISPR Therapeutics announced that their jointly developed CRISPR gene editing therapy CASGEVY has been conditionally approved.
Great Market Potential: Important Nodes in the Domestic RSV Pharmaceutical Field Xiaoyaowan
December 14, 2023
Respiratory syncytial virus (RSV) is a common enveloped RNA virus that circulates in the winter and spring. It is mainly transmitted by direct contact with the nasal secretions and respiratory droplets of infected individuals.
How is the progress of China’s domestically produced PD-(L)1 “going global”? Yefenghong/PharmaSources
November 23, 2023
Recently, Coherus BioSciences announced that the FDA has approved the launch of PD-1 antibody toripalimab (marketed jointly by Junshi Biosciences and Coherus) for use in combination with gemcitabine/cisplatin as a first-line treatment for advanced recurre
Domestic Enterprises Have Fully Laid out the Blue Ocean of US$10 Billion, and CAR-T Therapy Must Overcome the Achilles' Heel of Solid Tumor 203 Spuer/PharmaSources
August 07, 2023
The solid tumor is one of the two most deeply developed fields in CAR-T therapy, thus it is extremely urgent to overcome solid tumor in CAR-T therapy, considering domestic market access policy and current biomedical capital environment.